Ashok K Singh1* and Aakansha Singh2
1Postdoctoral Research Trainee, Pennsylvania State University, Penn State College of
Medicine, Hershey, PA, USA
2Associate Research Analyst, Clarivate Analytics, Hyderabad, Telangana, India
*Corresponding Author: Ashok K Singh, Postdoctoral Research Trainee, Pennsylvania State University, Penn State College of Medicine, Hershey, PA, USA.
Received: June 20, 2020; Published: June 26, 2020
Adoptive cell therapies (ACT) that redirect T cells to specifically target cancer using genetically engineered T cell receptor or chimeric antigen receptor T cells are emerging forms of immunotherapy. Natural killer (NK) cells serve as a crucial first line of defense against tumors and can be activated rapidly to target and kill tumor cells without prior sensitization. NK cells are winning candidates for use in ACT because matching to a specific patient is not required. Thus, making an off-the-shelf NK therapy product could be possible.
Citation: Ashok K Singh and Aakansha Singh. “Loading sd-rxRNAi into Tumors: Are We Getting Close with TGF-β1 Targeting?".Acta Scientific Pharmaceutical Sciences 4.8 (2020): 01-02.
Copyright: © 2020 Ashok K Singh and Aakansha Singh. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Open Access by
Acta Scientific is licensed under a Creative Commons Attribution 4.0 International License
Based on a work at https://actascientific.com
ff
